Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Inhibikase names Kailera CMO Scott Wasserman to board, Berman resignsOct 20PeopleIKT-001Inhibikase Therapeutics
Amgen gets FDA biosimilar supplement approval for RIABNI; posts new evolocumab PK trialOct 2Weekly roundup, 5 itemsAmgenapremilastUpdated
Amgen registers Phase 4 trial testing Repatha's effect on coronary plaque burdenSep 4Trial updateAmgenevolocumab
Amgen posts sotorasib trial results, updates Neupogen and Repatha labels; ITP trial recruitsJul 16Weekly roundup, 5 itemsAmgenevolocumab